Elevated Annexin II in Drug Resistant Lung Cancer Cells
Author Information
Author(s): S.P.C. Cole, M.J. Pinkoski, G. Bhardwaj, R.G. Deeley
Primary Institution: Cancer Research Laboratories, Queen's University, Kingston, Ontario, Canada
Hypothesis
The study investigates the role of elevated Annexin II expression in the multidrug resistant small cell lung cancer cell line H69AR.
Conclusion
The study found that the H69AR cell line expresses significantly higher levels of the 3.186 antigen, identified as Annexin II, compared to the sensitive H69 cell line.
Supporting Evidence
- H69AR cells show 5 to 6-fold higher levels of the 3.186 antigen compared to H69 cells.
- The study confirms that the 3.186 antigen is identical to p36, a member of the annexin family.
- Monoclonal antibodies against the 3.186 antigen were developed to study its role in drug resistance.
Takeaway
Researchers found that a protein called Annexin II is much more common in a type of lung cancer cell that resists treatment, which might help explain why these cells are hard to kill with drugs.
Methodology
The study used in vitro translation and molecular cloning techniques to analyze mRNA levels and identify the 3.186 antigen.
Want to read the original?
Access the complete publication on the publisher's website